Li
Su
abc,
Yaouba
Souaibou
abd,
Laurence
Hôtel
b,
Christophe
Jacob
a,
Peter
Grün
c,
Yan-Ni
Shi
ce,
Alicia
Chateau
f,
Sophie
Pinel
f,
Helge B.
Bode
ceghi,
Bertrand
Aigle
*b and
Kira J.
Weissman
*a
aUniversité de Lorraine, CNRS, IMoPA, F-54000 Nancy, France. E-mail: kira.weissman@univ-lorraine.fr
bUniversité de Lorraine, INRAE, DynAMic, F-54000 Nancy, France. E-mail: bertrand.aigle@univ-lorraine.fr
cMax-Planck-Institute for Terrestrial Microbiology, Department of Natural Products in Organismic Interactions, 35043 Marburg, Germany
dIPHC, UMR 7178, CNRS, Université de Strasbourg, Equipe de Chimie Analytique des Molécules Bioactives et Pharmacognosie, Illkirch, France
eMolecular Biotechnology, Department of Biosciences, Goethe University Frankfurt, Frankfurt am Main, Germany
fUniversité de Lorraine, CNRS, CRAN, F-54000 Nancy, France
gChemical Biology, Department of Chemistry, Philipps University of Marburg, 35043 Marburg, Germany
hSenckenberg Gesellschaft für Naturforschung, 60325 Frankfurt am Main, Germany
iCenter for Synthetic Microbiology (SYNMIKRO), University of Marburg, 35043 Marburg, Germany
First published on 22nd January 2025
The polyketide specialized metabolites of bacteria are attractive targets for generating analogues, with the goal of improving their pharmaceutical properties. Here, we aimed to produce C-26 derivatives of the giant anti-cancer stambomycin macrolides using a mutasynthesis approach, as this position has been shown previously to directly impact bioactivity. For this, we leveraged the intrinsically broad specificity of the acyl transferase domain (AT12) of the modular polyketide synthase (PKS), which is responsible for the alkyl branching functionality at this position. Feeding of a panel of synthetic and commercially available dicarboxylic acid ‘mutasynthons’ to an engineered strain of Streptomyces ambofaciens (Sa) deficient in synthesis of the native α-carboxyacyl-CoA extender units, resulted in six new series of stambomycin derivatives as judged by LC-HRMS and NMR. Notably, the highest product yields were observed for substrates which were only poorly accepted when AT12 was transplanted into a different PKS module, suggesting a critical role for domain context in the overall functioning of PKS proteins. We also demonstrate the superiority of this mutasynthesis approach – both in terms of absolute titers and yields relative to the parental compounds – in comparison to the alternative precursor-directed strategy in which monoacid building blocks are supplied to the wild type strain. We further identify a malonyl-CoA synthetase, MatB_Sa, with specificity distinct from previously described promiscuous enzymes, making it a useful addition to a mutasynthesis toolbox for generating atypical, CoA activated extender units. Finally, we show that two of the obtained (deoxy)-butyl-stambomycins exhibit antibacterial and antiproliferative activities similar to the parental stambomycins, while an unexpected butyl-demethyl congener is less potent. Overall, this works confirms the interest of biosynthetic pathways which combine a dedicated route to extender unit synthesis and a broad specificity AT domain for producing bioactive derivatives of fully-elaborated complex polyketides.
Experimentally, AT swapping consists of exchanging only the AT domain within a module of interest for an AT of distinct substrate specificity from another module, either sourced from the same or a different PKS.6–10 This approach has resulted in various hybrid metabolites, with recent work revealing highly effective domain boundaries for such exchanges.11,12 Concerning the complementation strategy, it involves selectively inactivating the native AT within a particular PKS module and rescuing its activity via a co-expressed trans-acting AT.4,13,14 Drawbacks of this approach include that it depends on the ability of the trans-ATs to recognize noncognate ACPs as partners,14 and the typically limited substrate (for malonate)4 of these enzymes. Finally, AT active site mutagenesis has been used in efforts to redirect and/or broaden innate AT substrate selectivity.15–17 Despite the availability of several AT crystal structures,18–21 this approach remains hampered by the paucity of co-complex structures in the presence of native extender units. Indeed, all such attempts to date to switch AT specificity have only resulted in a shift in substrate preference,4,15–17,22 a result potentially explained by the currently insufficient predictive power of the identified AT substrate-binding motifs.12
An alternative approach towards polyketide structural diversification is to exploit the intrinsically broad substrate specificity of certain ATs, and challenge them with alternative building blocks via precursor-directed biosynthesis (PDB) and/or mutasynthesis.23–31 In the case of PDB (Fig. 1a), the supplied ‘mutasynthons’ must compete with the native substrates, while in a mutasynthetic strategy (Fig. 1b), precursor biosynthesis is disabled,2 and thus the pathway depends, at least in principle, on the presence of the exogenous building block in order to function. To date, multiple functional groups including several not found naturally in polyketides have been incorporated into polyketides in this manner, including alkyne, azide, and halogen moieties.24–31
![]() | ||
Fig. 1 Schematic overview of (a) precursor-directed biosynthesis (PDB), (b) mutasynthesis approaches,23 (c) biosynthesis of CoA-linked polyketide synthase extender units via crotonyl-CoA carboxylase/reductase (CCR) and MatB enzymes (see details in Fig. S1†), and the (d) mutasynthesis strategy applied to stambomycin biosynthesis. Commercially sourced and synthetic malonic acids incorporating a wide variety of side chains were fed to the production culture of mutasynthesis mutant ATCC/OE484/Δ483. At least six of these alternative extender units were then successfully activated to their corresponding CoAs by the promiscuous MatB_Sa of S. ambofaciens, and incorporated into the pathway by AT12, resulting in stambomycin derivatives bearing modifications at C-26, a position which directly impacts the bioactivity.42 The hydroxylation at C-28 (red circle) was found to occur to variable extents, but the hydroxylation at C-50 and mycaminosylation went to completion. |
Evidently, a critical parameter for successful PDB and/or mutasynthesis is exogenous precursor supply. Previous in vitro studies have shown that commercially available malonyl-CoA derivatives can be used as mutasynthons.32 However, this method is not suitable for in vivo feeding studies due to poor acyl-CoA membrane permeability.33 This problem can be addressed by the use of synthetic N-acetylcysteamine thioesters (SNACs) which mimic the distal end of CoA, but leveraging them in large-scale applications is complicated by the need to synthesize the compounds, as well as their cellular toxicity.34 A promising alternative is a chemoenzymatic approach, in which a fed monomer (mono- or di-acid) is activated to its corresponding malonyl-CoA derivative in cellulo by an appropriate enzyme – either a crotonyl-CoA reductase/carboxylase (CCR)35–38 homologue or a broad-specificity malonyl-CoA synthetase (MatB)18,34,39–41 homologue (Fig. 1c and S1†).
ATs which recognize atypical extender units typically show broad substrate specificity relative to their malonate- or methylmalonate equivalents.12,38 Even among such domains, a particularly promiscuous AT participates in the biosynthesis of the stambomycin family of 51-membered macrolides in S. ambofaciens ATCC23877 (ref. 42–44). This domain (AT12) naturally recruits at least six atypical alkyl malonyl-CoA-derived extender units: (4-methylhexyl)malonyl-CoA, (5-methylhexyl)malonyl-CoA, (4-methylpentyl)malonyl-CoA, n-hexylmalonyl-CoA, n-pentylmalonyl-CoA and (4,5-dimethylhexyl)malonyl-CoA (Fig. 1d). This broad specificity results in six stambomycins (A–F, respectively) bearing distinct side chains at C-26. Notably, modifications at this position directly impact the biological properties of the metabolites, with stambomycins C/D showing improved antiproliferative activity towards a range of human cancer cell lines.42 In contrast to the typical CCR-mediated synthesis of polyketide extender units via reductive carboxylation of α,β-unsaturated acyl-thioesters,35–38 the stambomycin precursors are generated by direct carboxylation of medium chain acyl-CoA substrates catalyzed by the ATP-dependent enzyme SamR0483 (Fig. 1d).43 (Note: although SamR0483 was renamed MccB for medium chain acyl-CoA carboxylase β-subunit, we will refer to it here as SamR0483 in line with the gene nomenclature43). The acyl-CoAs derive either from the corresponding amino acids via the consecutive action of the branched-chain α-keto acid dehydrogenase complex and primary metabolic fatty acid synthase enzymes (FabH and FabF), or via direct conversion of the corresponding fatty acids to their CoA thioesters by SamR0482, a medium chain fatty acyl-CoA ligase homologue.43 Notably, SamR0482 and SamR0483 together were shown to generate the corresponding extender units from 6-azidohexanoic acid and 8-nonionic acid, resulting in stambomycin C-26 analogues bearing azide and alkyne groups43 (Fig. 1d). Thus, in addition to the intrinsically broad specificity of AT12 and all twelve downstream PKS modules, SamR0482 and SamR0483 exhibit useful substrate tolerance.
Here we aimed to further exploit the intrinsic flexibility of the stambomycin pathway to access a larger panel of analogues by mutasynthesis for biological testing (Fig. 1d). For this, we first disrupted the supply of the native extender units by mutational inactivation of samR0483. We then fed the resulting strains with 12 commercially-available or synthetic malonic acid derivatives, relying either on the intrinsic promiscuity of the S. ambofaciens MatB (MatB_Sa) or heterologously-expressed MatB from S. cinnamonensis45 for activation to their respective CoA thioesters. Six of the derivatives resulted in stambomycin analogues some of which were hydroxylated at C-28, including four at yields sufficient for structure elucidation by NMR and biological activity tests. We further show that MatB_cinna is more effective than the native S. ambofaciens homologue at monomer activation, while direct comparison of the yields obtained by PDB and mutasynthesis confirms the superiority of the latter approach for analogue generation.
![]() | ||
Fig. 2 Analysis by (a) mass spectrometry and (b) UV at λmax 238 nm of ATCC/OE484 (control) and mutants for mutasynthesis. The TIC (total ion chromatogram) and UV spectrum of ATCC/OE484/Δ483 clearly show that production by the mutant of the stambomycins (peaks highlighted in grey) is almost abolished. The indicated yields of stambomycins (AB and CD) in the wild type and mutant strains are based on integration of the EIC (extracted ion chromatogram) peaks and a previously generated standard curve for stambomycin AB.44 The calculated areas represent the average of the analysis of at least two independent clones of each strain. |
To confirm that the substantial decrease in stambomycin production in the ATCC/OE484/Δ483 mutant was due to the loss function of SamR0483, we carried out a complementation experiment by integrating the samR0483 gene into the genome of ATCC/OE484/Δ483 mutant under the control of the constitutive promoter ermE*p.51 Although the observed complementation was incomplete (31% stambomycin yields relative to wt (Fig. 2)), restoration of biosynthesis nonetheless supports the proposed essential role for SamR0483 in the pathway.43 We therefore used mutant ATCC/OE484/Δ483 as our base strain for the mutasynthesis experiments.
Analysis by LC-HRMS of cell pellets following extraction with methanol showed unexpectedly, that for all fed extracts with the exception of thiophenyl-malonic acid and thienylmethyl-malonic acid for which there was no change, peaks corresponding to stambomycins A/B and C/D were always present, and at yields 2–8 times higher than those from the unsupplemented ATCC/OE484/Δ483 mutasynthesis mutant (Tables 1, S7 and Fig. S3†). To explain this surprising observation, we propose that the fed malonic acid derivatives somehow induce expression of the identified SamR0483 homologues (Table S1†), which can then more substantially compensate for the loss of SamR0483. However, this mechanism remains to be verified directly by targeted inactivation of this set of genes.
Malonic acid derivatives | Titers of stambomycins and their analogues (mg L−1) | ||
---|---|---|---|
Stambomycins (A–D) | Analogue (with C-28 OH) | Deoxy analogue (lacking C-28 OH) | |
Control (no supplementation) | 0.09 | n.d | n.d |
Ethyl- | 0.77 | n.d | 0.00077 (1) |
Isopropyl- | 0.32 | n.d | n.d |
Allyl- | 0.17 | 0.0018 (2) | 0.34 (3) |
Butyl- | 0.17 | 3.9 (4) | 18.56 (5) |
Benzyl- | 0.43 | 0.025 (6) | 0.049 (7) |
Octyl- | 0.76 | 0.07 (8) | n.d |
Phenylpropyl- | 0.53 | n.d | n.d |
Phenoxypropyl- | 0.21 | 0.0098 (9) | 0.012 (10) |
Thiophenyl- | 0.08 | n.d | n.d |
Thienylmethyl- | 0.09 | n.d | n.d |
Propargyl- | 0.41 | n.d | n.d |
6-Bromohexyl- | 0.55 | 0.025 (11) | n.d |
Nevertheless, we observed that supplementation with ethyl- (giving rise to compound 1), allyl- (2 and 3), butyl- (4 and 5), benzyl- (6 and 7), phenoxypropyl- (9 and 10), and 6-bromohexyl-malonic acids (11) yielded new peaks relative to the control, all with masses consistent with the expected C26-modified stambomycin analogues (Tables 1, S7 and Fig. S3†). It must nonetheless be noted that the exact mass of the 6-bromohexyl-malonic acid analogue corresponds to a structure lacking two of the expected hydrogens (Fig. S3†). This structural variation may correspond to a ketone at position C-28 instead of the expected hydroxyl functionality, due to over-oxidation by the P450 hydroxylase SamR0478.52 Indeed, SamR0478 belongs to the CYP107H family whose members have been shown to catalyse ketonization of C–H bonds, but this hypothesis remains to be verified. In contrast, the phenylpropyl-, thiophenyl-, thienylmethyl-, and propargyl-malonic acids failed to be incorporated (Tables 1, S5, S7 and Fig. S3†). A peak at 1390.9546 ([M + H]+, C74H130NO22+; r.t. 25.4 min) found in the octyl-fed extract (Table 1) requires further investigation in order to determine whether it corresponds to a novel octyl-stambomycin (8) or the native stambomycin F53 (r.t. 24.2 min), as the two masses are identical (Table S5†). Arguing for the formation of octyl-stambomycin, however, the observed yield of the metabolite is 9.2% relative to the stambomycins A–D (Fig. S3†), while the typical titers of stambomycin F are only 2.5% (Fig. S4†).
Biosynthesis of the parental stambomycins involves C-28 hydroxylation by the P450 hydroxylase SamR0478, as well as on-line C-50 hydroxylation by a second P450 SamR0479 to generate the nucleophile required for macrolide formation.54 For five of the successfully incorporated precursors (ethyl-, allyl-, butyl-, benzyl- and phenoxypropyl-malonate), the macrocyclic stambomycin analogues lacking C-28 hydroxylation (the ‘deoxy’ forms, 1, 3,5, 7 and 10) were the main or even sole products (i.e. no ethyl-stambomycin was detected), accounting for 55.3–99.5% of the total yields based on their relative abundance in the mass spectra. In contrast, 6-bromohexyl-stambomycin (11) is the sole analogue observed in the 6-bromohexyl feeding experiments. This observation suggests that SamR0478 strongly prefers its native substrates or at minimum closely similar chains (Fig. 1). In contrast, in no case were aglycone analogues detected in the fed extracts (data not shown), showing that the post-PKS glycosylase SamR0481, exhibits broad substrate tolerance, at least towards substrates of comparable size to the parental stambomycins44 (Fig. 1).
To directly address the first possibility, we introduced promiscuous MatB_cinna45 into mutant ATCC/OE484/Δ483, resulting in mutant ATCC/OE484/Δ483/MatB_cinna. Mutants ATCC/OE484/Δ483 and ATCC/OE484/Δ483/MatB_cinna were then fed with ethyl-, allyl-, butyl- and benzyl-malonic acids, followed by quantification of the resulting analogues produced by the two strains. For this, erythromycin (1 mM added during the work-up step) was used as an internal standard for the LC-HRMS analyses to control for any differences in extraction efficiency. The obtained data demonstrated that the presence of MatB_cinna improved the incorporation of ethyl-, allyl- and benzyl-malonic acids (Fig. 3a, b, d and Table S8†), resulting in a nearly 2-fold increase relative to the parental strain which contains only MatB_Sa. Indeed, recent work has demonstrated that MatB_cinna efficiently converts ethyl-, allyl- and benzyl-malonic acid to their corresponding CoA forms,34 which is consistent with the results obtained here. In contrast, levels of incorporation of butyl-malonic acid by the two mutants were essentially identical (88% vs. 71%, Fig. 3c and Table S8†), reflecting the fact that MatB_cinna is poorly active with butyl-diacid.34
With the aim of elucidating the structures of certain analogues, we therefore used ATCC/OE484/Δ483/MatB_cinna to obtain allyl-incorporated stambomycin, and the original mutant ATCC/OE484/Δ483 to produce the butyl variant. This approach resulted in sufficient quantities of deoxy-allyl-stambomycin (3) (0.7 mg L−1) to allow for its purification (the yields of allyl-stambomycin (2) were inadequate), while three compounds (22.5 mg L−1 combined yield of the two most abundant compounds) were purified from extracts of ATCC/OE484/Δ483 fed with butyl-malonic acid (final yields, deoxy-allyl-stambomycin (3): 1.8 mg; butyl-stambomycin (4): 11.6 mg; deoxy-butyl-stambomycin (5): 36.3 mg; C-24-demethyl-butyl-stambomycin (12) (vide infra): 3.1 mg). The structures of these four compounds were elucidated by comprehensive NMR and HRMS analysis (Fig. S5–S29†), yielding data consistent with deoxy-allyl-stambomycin (3), butyl-stambomycin (4) and deoxy-butyl-stambomycin (5). Concerning the third butyl derivative, comparison of the obtained NMR data with that of butyl-stambomycin (4) revealed a methyl signal missing from the 1H NMR spectrum (δH 1.64) corresponding to the methyl at C-24, and the shift of an olefinic proton from δH 5.22 to δH 5.43. Additionally, coupling constants of 15.4 and 8.0 were observed for H-25 (Fig. S17–S22†). These data are all consistent with a C-24-demethyl derivative of butyl stambomycin (12). Such a compound would arise from alternative incorporation of malonyl-CoA instead of methylmalonyl-CoA by AT13. Given the intrinsically broad specificity of AT12, it is not unreasonable that a second AT within the same system (i.e. AT13) might also exhibit a certain level of promiscuity. In support of this idea, reinspection of wild type extracts revealed a peak with a mass of 1334.8911 (C70H128NO22+; m/z [M + H]+ = 1334.8922, Δppm = −0.8), which matches that of a demethyl derivative of stambomycin E (Fig. S4†) (note, it was not possible to conclusively identify analogous demethyl analogues of stambomycins AB, CD and F, as C-24-demethyl-stambomycins AB would have the same exact masses as stambomycins CD, C-24-demethyl-stambomycins CD, the same mass as stambomycin E, and C-24-demethyl-stambomycin F the same as stambomycins AB).
Next, we tested the antiproliferative activities against two human cancer cell lines, U87-MG glioblastoma cells (brain cancer) (ATCC HTB-14) and MDA-MB-231 (ATCC HTB-26) cells, which are commonly used to model late-stage breast cancer. MTT assays revealed significant and similar antiproliferative activities against the two lines for the butyl-stambomycin and its deoxy form (Fig. S31†) with IC50 values around 1 μM for both the U87 and the MDA-MB-231 cells (Table S10†). These values are in the range of those observed for the parental stambomycins42 and are better than those measured for the clinical anticancer agent doxorubicin used as a control (Table S10†). Cell counting further confirmed that the inhibition observed in the MTT assays was related to cell death (Fig. S31†). As observed with the anti-bacterial assays, the C-24-demethyl derivative (12) of butyl-stambomycin and the allyl analogue (3) were significantly less active against the two cancer cell lines (Table S9 and Fig. S31†).
Supplementation of ATCC/OE484/Δ483 with suitable precursors yielded 6 novel series of stambomycin analogues at varying yields. Derivatives obtained in this way incorporated ethyl, butyl, allyl, benzyl, phenoxypropyl and 6-bromohexyl groups at C-26 instead of the native chains (Table 1) (initial evidence was also obtained for the C-26 octyl analogue). For each of the analogues except that bearing the 6-bromohexyl group which was fully modified, a major proportion of the compounds lacked the C-28 hydroxylation catalyzed by the P450 enzyme SamR0478. It is also notable that feeding of butylmalonic acid resulted in almost exclusive production of butyl-stambomycin relative to residual stambomycins A–D, whereas the native metabolites dominated in previous precursor-directed biosynthesis experiments.43 Indeed, in our hands, the PDB approach only yielded a single novel derivative when a limited series of monoacid substrates was fed. Overall, successful production of this panel of analogues depended on the intrinsic substrate tolerance of three distinct enzymatic events in the pathway: the MatB_Sa-catalyzed activation of the diacids to their CoA thioesters, substrate selection and ACP loading by AT12, and recognition of the modified intermediates by the downstream PKS modules, the C-50 hydroxylase SamR0479,54 and SamR0481-mediated mycaminosylation. It is also worth noting that producing comparable analogues using synthetic chemistry would require their total synthesis. In future, the approach described here could be coupled with metabolic engineering to introduce pathways dedicated to the synthesis of alternative extender units,67 thereby alleviating the dependence on costly commercial building blocks and/or chemical synthesis.
Nonetheless, the intrinsically broad specificity of AT12 and the overall PKS system did not translate into universal acceptance of all alternative building blocks. Intriguingly, despite the bulky nature of the (methyl)pentyl/(methyl)hexyl side chains of the native extender units, the non-native analogues showing the highest level of incorporation were significantly shorter (i.e. butyl and allyl). The efficient incorporation of butyl-malonic acid is also notable for a second reason, as it suggests that MatB_Sa has unusually high activity towards this substrate, which was not seen with MatB_cinna34 and MatB_Rt41 despite their intrinsic promiscuity. This hypothesis is also supported by the fact that expression of MatB_cinna alongside MatB_Sa did not improve incorporation of butyl-malonate by the strain. Concerning the substrates which were not accepted (isopropyl, phenylpropyl-, thiophenyl-, thienylmethyl- and propargylmalonic acid), it is not possible to conclusively identify the enzymatic bottleneck(s), as none of these substrates were directly evaluated in previous work with MatB_cinna,34 but the absence of prematurely released chain extension intermediates points to either AT12 or MatB.
Our positive incorporation results notably contrast with recent data obtained from an engineered swap of AT12 into module 6 of the erythromycin (DEBS) PKS.12 In this case, analysis in vitro with purified hybrid protein and a series of α-carboxyacyl-CoA substrates revealed essentially no activity towards ethyl- and allylmalonyl-CoA, comparable but low activity with propyl-, butyl-, pentyl-, hexylmalonyl-CoA, and a pronounced preference for isopentyl-CoA. This result taken alongside other obtained data was interpreted to show that atypical AT domains can incorporate extender units which are equal in size or slightly larger than their native substrates.12 Indeed, AT12 was predicted by AlphaFold2 (ref. 12 and 68) to possess one of the largest active site cavity volumes among the evaluated ATs, in accord with the high steric demands of its native substrates. At this stage, it is difficult to reconcile the two sets of data, particularly as incorporation of butyl-malonyl-CoA in our hands resulted in mature analogues at yields comparable to that of the parental stambomycins (20–30 mg L−1).42 Either the AT in its native context exhibits a more relaxed specificity, or the specificity of AT12 was unchanged, but the tolerance of the other DEBS module 6 domains was negatively impacted by introduction of this heterologous AT (in the presence of alternative non-native ATs, DEBS module 6 accepted both allyl- and butylmalonyl-CoA with good efficiency12). Another possible explanation, however, is that insertion of AT12 into the module caused structural perturbation, which impacted turnover. Indeed, the AT swapped modules which gave the lowest purification yields relative to wild type also exhibited the most restricted substrate specificities.12 In any case, the cumulative results point to a complex interplay between the AT and the remaining domains of the PKS in determining the efficacy with which alternative building blocks can be incorporated into engineered polyketides. This parameter will need to be considered in future PKS engineering experiments based on AT swapping.11,12
Our observation that the butyl (C4) congeners (4 and 5) retained good activity relative to the native metabolites (linear and branched C5 and C6 side chains) demonstrates a certain tolerance to the chain length and functionality at the C-26 position. However, the allyl analogue (C3) (3) was markedly less potent, an effect which may be due to the further reduced length, or the presence of the double bond. Our data also confirm an earlier observation made with the parental stambomycins46 that the hydroxylation at C-28 has no significant effect on the biological activities of the analogues. Interestingly, the methyl group at C-24 appears to contribute significantly to both the antibacterial and antiproliferative properties of the derivatives, as its absence (i.e.12) results in a sharp decrease in bioactivity. Potential reasons for this drop include reduced lipophilicity and thus biomembrane solubility, or the lack of an important conformational constraint on the macrolides. We note that the effect of methylation on biological interactions has strong precedence in the literature.69
Finally, given the observed specificity differences between MatB_Sa and MatB_cinna, it would be of interest to attempt to further broaden the substrate tolerance of MatB_Sa by structure-guided mutagenesis. Notably, an engineered version of MatB_Rt (T207G/M306I) showed improved catalytic activity toward ethyl-, propargyl- and allyl-malonic acids, as well some tolerance towards isopropyl-, butyl-, phenyl-, and azido-malonic acids.41 The two residues corresponding to T207 and M306 in MatB_Sa are V190 and M293 (Fig. S2†), which could be modified in attempts to similarly broaden the substrate scope of MatB_Sa. In parallel, it would be worth targeting for inactivation the identified homologues of SamR0483 in order to reduce the background synthesis of the parental stambomycins, potentially boosting the yields of the novel derivatives. We also envision that an analogous mutasynthesis strategy could be applied to other diversity oriented pathways but with supplementation using one of the native precursors – redirecting the pathway to production of a single natural compound which should simplify purification and subsequent structure elucidation.70 Together, such approaches should further expand the enzymatic toolbox available for efficient AT-based polyketide analogue generation.
Footnote |
† Electronic supplementary information (ESI) available. See DOI: https://doi.org/10.1039/d4sc06976e |
This journal is © The Royal Society of Chemistry 2025 |